PDF herunterladen
Exp Clin Endocrinol Diabetes 2018; 126(06): 333-341
DOI: 10.1055/a-0577-7574
Review
© Georg Thieme Verlag KG Stuttgart · New York

Amiodarone-Induced Thyroid Dysfunction: A Clinical Update

Mohamed Nabil Elnaggar
1   Department of Endocrinology, Diabetes & Metabolism, University Hospitals of Morecambe Bay NHS Foundation Trust, United Kingdom, LA1 4RP
4   Internal Medicine Department, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt
,
Kahtan Jbeili
1   Department of Endocrinology, Diabetes & Metabolism, University Hospitals of Morecambe Bay NHS Foundation Trust, United Kingdom, LA1 4RP
,
Nik Nik-Hussin
2   Department of Radiology and Nuclear Imaging Services, University Hospitals of Morecambe Bay NHS Foundation Trust, United Kingdom, LA1 4RP
,
Mohandas Kozhippally
3   Department of Medicine, Good Hope Hospital, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, B75 7RR
,
Joseph M Pappachan
1   Department of Endocrinology, Diabetes & Metabolism, University Hospitals of Morecambe Bay NHS Foundation Trust, United Kingdom, LA1 4RP
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 02. Januar 2018
revised 06. Februar 2018

accepted 11. Februar 2018

Publikationsdatum:
20. März 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Erratum zu diesem Artikel:

Correction: Amiodarone-Induced Thyroid Dysfunction: A Clinical UpdateExp Clin Endocrinol Diabetes 2018; 126(06): e1-e1
DOI: 10.1055/a-0650-8694

Abstract

Amiodarone is one of the most commonly prescribed antiarrhythmic agents in clinical practice owing to its efficacy, even with high toxicity profile. The high iodine content and the prolonged biological half-life of the drug can result in thyroid dysfunction in a high proportion of patients treated with amiodarone even after cessation of amiodarone. Both hypothyroidism and hyperthyroidism are common side effects that mandate regular monitoring of patients with thyroid function tests. Amiodarone-induced hypothyroidism (AIH) is diagnosed and managed in the same way as a usual case of hypothyroidism. However, differential diagnosis and clinical management of amiodarone-induced thyrotoxicosis (AIT) subtypes can be challenging. With the aid of a case snippet, we update the current evidence for the diagnostic work up and management of patients with amiodarone-induced thyroid dysfunction in this article.

Key words

Amiodarone-induced hypothyroidism (AIH) - amiodarone-induced thyrotoxicosis (AIT) - cardiac arrhythmias - anti-thyroid drugs - radionuclide thyroid uptake scan
 

  • References

  • 1 Claro JC, Candia R, Rada G. et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database of Syst Rev 2015; Cd008093
    PubMedGoogle Scholar
  • 2 Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials. Eur Heart J 2009; 30: 1245-1253
    CrossrefPubMedGoogle Scholar
  • 3 Dixon DL, Dunn SP, Kelly MS. et al. Effectiveness of pharmacist-led amiodarone monitoring services on improving adherence to amiodarone monitoring recommendations: A systematic review. Pharmacotherapy 2016; 36: 230-236
    CrossrefPubMedGoogle Scholar
  • 4 Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis. Mayo Clin Proc 2009; 84: 234-242
    CrossrefPubMedGoogle Scholar
  • 5 Benjamens S, Dullaart RPF, Sluiter WJ. et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol 2017; 177: 9-14
    CrossrefPubMedGoogle Scholar
  • 6 Bogazzi F, Tomisti L, Bartalena L. et al. Amiodarone and the thyroid: A 2012 update. J Endocrinol Invest 2012; 35: 340-348
    PubMedGoogle Scholar
  • 7 Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-714
    CrossrefPubMedGoogle Scholar
  • 8 Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgrad Med J 1986; 62: 909-914
    CrossrefPubMedGoogle Scholar
  • 9 Epstein AE, Olshansky B, Naccarelli GV. et al. Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. Am J Med 2016; 129: 468-475
    CrossrefPubMedGoogle Scholar
  • 10 Kinoshita S, Hayashi T, Wada K. et al. Risk factors for amiodarone-induced thyroid dysfunction in Japan. J Arrhythm 2016; 32: 474-480
    PubMedGoogle Scholar
  • 11 Martino E, Aghini-Lombardi F, Bartalena L. et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med 1994; 154: 2722-2726
    CrossrefPubMedGoogle Scholar
  • 12 Jabrocka-Hybel A, Bednarczuk T, Bartalena L. et al. Amiodarone and the thyroid. Endokrynol Pol 2015; 66: 176-186
    PubMedGoogle Scholar
  • 13 Wiersinga WM. The role of thyroid hormone nuclear receptors in the heart: Evidence from pharmacological approaches. Heart Fail Rev 2010; 15: 121-124
    CrossrefPubMedGoogle Scholar
  • 14 Bogazzi F, Bartalena L, Martino E. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab 2010; 95: 2529-2535
    CrossrefPubMedGoogle Scholar
  • 15 Ahmed S, Van Gelder IC, Wiesfeld AC. et al. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin endocrinol (Oxf) 2011; 75: 388-394
    CrossrefPubMedGoogle Scholar
  • 16 Tomisti L, Urbani C, Rossi G. et al. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2016; 39: 585-591
    CrossrefPubMedGoogle Scholar
  • 17 Zhong B, Wang Y, Zhang G. et al. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: A systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology 2016; 134: 366-371
    CrossrefPubMedGoogle Scholar
  • 18 Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025-2034
    CrossrefPubMedGoogle Scholar
  • 19 Yagishita A, Hachiya H, Kawabata M. et al. Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. Circ J 2013; 77: 2898-2903
    CrossrefPubMedGoogle Scholar
  • 20 Cohen-Lehman J, Dahl P, Danzi S. et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol 2010; 6: 34-41
    CrossrefPubMedGoogle Scholar
  • 21 Tomisti L, Rossi G, Bartalena L. et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol 2014; 171: 363-368
    CrossrefPubMedGoogle Scholar
  • 22 Piga M, Serra A, Boi F. et al. Amiodarone-induced thyrotoxicosis. A review. Minerva endocrinol 2008; 33: 213-228
    PubMedGoogle Scholar
  • 23 Bogazzi F, Bartalena L, Brogioni S. et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997; 7: 541-545
    CrossrefPubMedGoogle Scholar
  • 24 Eaton SEM, Euinton HA, Newman CM. et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002; 56: 33-38
    CrossrefPubMedGoogle Scholar
  • 25 Theodoraki A, Vanderpump MP. Thyrotoxicosis associated with the use of amiodarone: The utility of ultrasound in patient management. Clin Endocrinol (Oxf) 2015; Dec 7 doi: DOI: 10.1111/cen.12988. [Epub ahead of print]
    PubMedGoogle Scholar
  • 26 Tanda ML, Piantanida E, Lai A. et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: Similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf) 2008; 69: 812-818
    CrossrefPubMedGoogle Scholar
  • 27 Wang J, Zhang R. Evaluation of 99 mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol 2017; 90: 20160836
    CrossrefPubMedGoogle Scholar
  • 28 Pattison DA, Westcott J, Lichtenstein M. et al. Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99 m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun 2015; 36: 356-362
    CrossrefPubMedGoogle Scholar
  • 29 Oki GC, Zantut-Wittmann DE, de Oliveira Santos A. et al. Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: A comparison with Tc-99m pertechnetate imaging. Clin Nucl Med 2010; 35: 223-227
    CrossrefPubMedGoogle Scholar
  • 30 Zhong B, Wang Y, Zhang G. et al. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: A systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology 2016; 134: 366-371
    CrossrefPubMedGoogle Scholar
  • 31 Bogazzi F, Martino E, Dell’Unto E. et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003; 26: 635-640
    CrossrefPubMedGoogle Scholar
  • 32 Bartalena L, Grasso L, Brogioni S. et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78: 423-427
    PubMedGoogle Scholar
  • 33 Pearce EN, Bogazzi F, Martino E. et al. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003; 13: 643-648
    CrossrefPubMedGoogle Scholar
  • 34 Bogazzi F, Tomisti L, Ceccarelli C. et al. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: A cautionary note. Clin Endocrinol (Oxf) 2010; 72: 133-134
    CrossrefPubMedGoogle Scholar
  • 35 Yiu K-H, Jim M-H, Siu C-W. et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009; 94: 109-114
    CrossrefPubMedGoogle Scholar
  • 36 Conen D, Melly L, Kaufmann C. et al. Amiodarone-Induced Thyrotoxicosis: Clinical course and predictors of outcome. J Am Coll Cardiol. 2007; 49: 2350-2355
    CrossrefPubMedGoogle Scholar
  • 37 O'Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: Left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154: 533-536
    CrossrefPubMedGoogle Scholar
  • 38 Narayana SK, Woods DR, Boos CJ. Management of Amiodarone-Related Thyroid Problems. Ther Adv Endocrinol Metab 2011; 2: 115-126
    CrossrefPubMedGoogle Scholar
  • 39 Bouvy ML, Heerdink ER, Hoes AW. et al. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug saf 2002; 11: 601-606
    CrossrefPubMedGoogle Scholar
  • 40 Martino E, Aghini-Lombardi F, Mariotti S. et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest. 1986; 9: 201-207
    CrossrefPubMedGoogle Scholar
  • 41 Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev. 1998; 50: 89-105
    PubMedGoogle Scholar
  • 42 Bartalena L, Brogioni S, Grasso L. et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 1996; 81: 2930-2933
    PubMedGoogle Scholar
  • 43 Bogazzi F, Bartalena L, Tomisti L. et al. Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. J Clin Endocrinol Metab 2007; 92: 556-562
    CrossrefPubMedGoogle Scholar
  • 44 Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: A review. Can J Cardiol 2009; 25: 421-424
    CrossrefPubMedGoogle Scholar
  • 45 Bogazzi F, Tomisti L, Rossi G. et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: A matched retrospective cohort study. J Clin Endocrinol Metab. 2009; 94: 3757-3762
    CrossrefPubMedGoogle Scholar
  • 46 Eskes SA, Endert E, Fliers E. et al. Treatment of amiodarone-induced thyrotoxicosis type 2: A randomized clinical trial. J Clin Endocrinol Metab. 2012; 97: 499-506
    CrossrefPubMedGoogle Scholar
  • 47 Gursoy A, Tutuncu NB, Gencoglu A. et al. Radioactive iodine in the treatment of type-2 amiodarone-induced thyrotoxicosis. J Nat Med Assoc 2008; 100: 716-719
    PubMedGoogle Scholar
  • 48 Czarnywojtek A, Warmuz-Stangierska I, Woliński K. et al. Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis. Pol Arch Med Wewn 2014; 124: 695-703
    PubMedGoogle Scholar
  • 49 Czarnywojtek A, Plazinska MT, Zgorzalewicz-Stachowiak M. et al. Dysfunction of the thyroid gland during amiodarone therapy: A study of 297 cases. Ther Clin Risk Manag 2016; 12: 505-513
    PubMedGoogle Scholar
  • 50 Houghton SG, Farley DR, Brennan MD. et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo clinic experience. World J Surg 2004; 28: 1083-1087
    CrossrefPubMedGoogle Scholar
  • 51 Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg 2006; 30: 1957-1961
    CrossrefPubMedGoogle Scholar
  • 52 Tomisti L, Materazzi G, Bartalena L. et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 2012; 97: 3515-3521
    CrossrefPubMedGoogle Scholar
  • 53 Tonnelier A, de Filette J, De Becker A. et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J 2017; 6: 108-112
    CrossrefPubMedGoogle Scholar
  • 54 Ezer A, Caliskan K, Parlakgumus A. et al. Preoperative therapeutic plasma exchange in patients with thyrotoxicosis. J Clin Apher 2009; 24: 111-114
    CrossrefPubMedGoogle Scholar
  • 55 Tsai WC, Pei D, Wang T. et al. The effects of combination therapy with propylthiuracil and cholesteramine in the the treatment of Grave’s hyperthyroidism. Clin Endocrinol (Oxf) 2005; 62: 521-524
    CrossrefPubMedGoogle Scholar
  • 56 Dickstein G, Shechner C, Adawi F. et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997; 102: 454-458
    CrossrefPubMedGoogle Scholar
  • 57 Bogazzi F, Aghini-Lombardi F, Cosci C. et al. Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. J Endocrinol Invest 2002; 25: 176-180
    CrossrefPubMedGoogle Scholar
  • 58 Bogazzi F, Bartalena L, Cosci C. et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: A prospective, randomized study. J Clin Endocrinol Metab 2003; 88: 1999-2002
    CrossrefPubMedGoogle Scholar
  • 59 Diamond TH, Rajagopal R, Ganda K. et al. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Intern Med J 2004; 34: 369-370 author reply 370–371
    CrossrefPubMedGoogle Scholar
  • 60 Zhu L, Zainudin SB, Kaushik M. et al. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinol Diab Metab Case Rep 2016; 2016: 160039
    PubMedGoogle Scholar
  • 61 Albino CC, Paz-Filho G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT). Clin Endocrinol (Oxf) 2009; 70: 810-811
    CrossrefPubMedGoogle Scholar
  • 62 Matrka L, Steward D, Falciglia M. et al. Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. Ear Nose Throat J 2008; 87: 702-704
    CrossrefPubMedGoogle Scholar
  • 63 Bogazzi F, Tomisti L, Ceccarelli C. et al. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: A cautionary note. Clin Endocrinol (Oxf) 2010; 72: 133-134
    CrossrefPubMedGoogle Scholar
  • 64 Hughes P, Freeman MK, Cohenour F. et al. Dronedarone: An alternative to amiodarone?. Consult Pharm 2010; 25: 555-569
    CrossrefPubMedGoogle Scholar
  • 65 Vamos M, Hohnloser SH. Amiodarone and dronedarone: An update. Trends Cardiovasc Med 2016; 26: 597-602
    CrossrefPubMedGoogle Scholar
  • 66 Bogazzi F, Dell'Unto E, Tanda ML. et al. Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. J Endocrinol Invest 2006; 29: 694-699
    CrossrefPubMedGoogle Scholar
  • 67 Padmanabhan H. Amiodarone and thyroid dysfunction. South Med J 2010; 103: 922-930
    CrossrefPubMedGoogle Scholar
  • 68 Maqdasy S, Batisse-Lignier M, Auclair C. et al. Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol 2016; 117: 1112-1116
    CrossrefPubMedGoogle Scholar